[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-junction-adenocarcinoma-siewert-ii-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-junction-adenocarcinoma-siewert-ii-iii":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100646237","molecular-characterization-of-tumor-microenvironment-interactions-to-predict-drug-resistance-in-gastric-and-gej-adenocarcinoma-100646237",false,"NCT07692477","Molecular Characterization of Tumor-Microenvironment Interactions to Predict Drug Resistance in Gastric and GEJ Adenocarcinoma","Molecular Characterization of Tumor-Microenvironment Interactions to Predict Drug Resistance to Perioperative Treatment in Patients With Gastric and Gastroesophageal Junction Adenocarcinoma","GASTROIMMUNE","Inclusion Criteria:\n\n1. Histologically confirmed adenocarcinoma of the stomach (gastric cancer, GC) or gastroesophageal junction (GEJ)\n2. Operable, locally advanced disease (T \\>= 2 and\u002For node-positive) according to AJCC 8th edition staging\n3. Candidate for perioperative chemotherapy with FLOT regimen combined with durvalumab, as per clinical practice\n4. Age \\>= 18 years\n5. Provision of written informed consent prior to any study-specific procedure\n\nExclusion Criteria:\n\n1. Presence of another active malignant disease\n2. Advanced or metastatic gastric\u002FGEJ cancer not eligible for surgical treatment\n3. Inability or unwillingness to provide written informed consent","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","OBSERVATIONAL","Surgical resection remains the only curative option for resectable gastric cancer, but perioperative FLOT chemotherapy is associated with substantial rates of chemoresistance and recurrence, largely driven by marked tumor heterogeneity. Recent data from the MATTERHORN phase III trial have shown that adding durvalumab to perioperative FLOT improves pathological complete response and survival, supporting this combination as a new standard of care for resectable gastric and gastroesophageal junction adenocarcinoma.\n\nThis observational multicenter study aims to characterize angiogenic and immune profiles within the tumor microenvironment and peripheral blood, in order to identify cellular and molecular signatures associated with response or resistance to perioperative FLOT plus durvalumab. Longitudinal biospecimen collection (PBMCs, serum, plasma, endoscopic biopsies, surgical specimens) will be integrated with multiparametric flow cytometry, single-cell transcriptomics and TCR\u002FBCR sequencing, immunohistochemistry, pathomics and multiplex immunoassays, to provide mechanistic insights and potential predictive biomarkers.",[25,26],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma (Siewert II-III)",[28,29,30,31,32,33,34],"tumor microenvironment","perioperative chemotherapy","FLOT","durvalumab","angiogenesis","single-cell RNA sequencing","biomarkers","NOT_YET_RECRUITING","2026-07-02",{"date":38,"type":39},"2026-07-09","ACTUAL",{"date":41,"type":21},"2026-09-01",{"date":43,"type":21},"2028-09-01",{"name":45,"class":46},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100528665","phase-2-camrelizumab-combined-with-chemotherapy-and-radiotherapy-perioperative-treatment-of-esophageal-gastric-junction-adenocarcinoma-100528665","NCT06163729","Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma","A Single-arm, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemotherapy Followed by Radiotherapy in the Perioperative Treatment of Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Male or female subjects aged from 18 to 80 years old;\n2. Patients with pathologically confirmed gastroesophageal junction adenocarcinoma (Siewert II-III)\n3. Resectable tumors with staging t3-4N0M0 or T1-4N+M0 confirmed by CT or MRI according to AJCC version 8 staging System;\n4. Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1);\n5. No prior anti-tumor therapy, including surgery, chemotherapy, radiotherapy, targeted and immunotherapy;\n6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry;\n7. Estimated life expectancy of more than 3 months;\n8. Adequate haematological, hepatic and renal functions defined by the protocol;\n9. Prior use of anti-tumor traditional Chinese medicine, proprietary Chinese medicine, immunomodulators (such as thymosin, interleukin, etc.) must be ≥2 weeks from the beginning of the study\n10. Negative blood pregnancy test at Screening for women of childbearing potential; Highly effective contraception for both male and female subjects if the risk of conception exists;\n11. The subjects participated in the study voluntarily, fully understood and informed the study and signed the informed consent;\n\nExclusion Criteria:\n\n1. Previous malignant disease within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ (bladder, cervical, colorectal, breast)；\n2. Any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy)); The subjects with childhood asthma who had been completely relieved and did not need any intervention or vitiligo in adulthood could be included, but the subjects who needed bronchodilator for medical intervention could not be included;\n3. Patients with congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU \u002F ml), hepatitis C (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C;\n4. Active tuberculosis;\n5. Prior organ transplantation, including allogeneic stem-cell transplantation；\n6. Other protocol-defined inclusion\u002Fexclusion criteria could apply.\n7. Used immunosuppressive drugs within 14 days before the first dose of study drug, excluding nasal and inhaled corticosteroids or physiological doses of systemic corticosteroids;\n8. Accination with live or live\u002Fattenuated viruses within 4 weeks of the first dose of camrelizumab and while on trial is prohibited except for administration of inactivated vaccines;\n9. History of uncontrolled intercurrent illness including hypertension, active infection, diabetes , hereditary bleeding , coagulopathy with a risk of bleedingor, cardiac diseases or symptoms;\n10. Patients with past and current interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-associated pneumonia, and severe impaired lung function may interfere with the detection and management of suspected drug-associated pulmonary toxicity;\n11. Known history of allergy to the drug components of this regimen;\n12. Presence of unresectable factors, including tumor, contraindications to surgery, or rejection of surgery;\n13. Major surgical procedures were performed within 4 weeks prior to initial administration;","80 Years",{"count":56,"type":21},68,"INTERVENTIONAL",[59],"PHASE2","This project intends to study the efficacy and safety of camrelizumab combined with chemotherapy followed by radiotherapy in the perioperative treatment of AEG.",[26],"RECRUITING","2024-02-01",{"date":65,"type":39},"2024-02-02",{"date":67,"type":39},"2022-08-25",{"date":69,"type":21},"2028-05-01",{"name":71,"class":46},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",1]